Annual Meeting

CIMT 2019 Annual Meeting

May 21 – 23, 2019

Rheingoldhalle Congress Center
Mainz, Germany

For more information, please go to

CIMT Satellites

CIMT actively participates in international cancer and immunology meetings by sponsoring sessions and workshops dedicated to the topic of cancer immunotherapy.

Tuesday, April 17, 2018, 6:00-8:00 p.m.
Chicago, Illinois

  The AACR Cancer Immunology (CIMM) Working Group
Town Hall and Reception
co-sponsored by the:
Association for Cancer Immunotherapy CIMT


6:00 – 6:30 p.m. 
   Opening remarks and Working Group overview
CIMM Chair Jedd D. Wolchok, New York, NY; CIMM Chair-Elect Dmitry I. Gabrilovich, Phildadelphia, PA

6:30 – 6:35 p.m.    Update on Cancer Immunology Research
Editors-in-Chief, Robert D. Schreiber, St. Louis, MO; Philip D. Greenberg, Seattle, WA

6:35 – 6:40 p.m.    Introduction, CIMT Leadership,  Cornelis J.M. Melief, Leiden, Netherlands

   6:40 – 7:00 p.m.    Individualized Cancer Vaccination – Current Status and Perspectives
Sebastian Kreiter, Mainz, Germany

7:00 - 7:20     How to Define a Good Tumor Neoepitope
Pramod K. Srivastava, Farmington, CT

7:20 - 7:25   Closing remarks, Dmitry I. Gabrilovich, Philadelphia, PA

7:25 – 8:00 p.m.    CIMM Networking reception

CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference

Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference

"Translating Science into Survival"
September 30-October 3, 2018, New York, NY, USA

The Cancer Research Institute (CRI), the Association for Cancer Immunotherapy (CIMT), the European Academy of Tumor Immunology (EATI), and the American Association for Cancer Research (AACR) are proud to once again join forces to sponsor the Fourth Annual CRI-CIMT-EATI-AACR INTERNATIONAL CANCER IMMUNOTHERAPY CONFERENCE, which will take place in New york, NY from September 30-October 3, 2018. 

The International Cancer Immunotherapy Conference covers all areas of inquiry in cancer immunology and immunotherapy. Launched in 2015, the meeting is jointly sponsored by the Cancer Research Institute (CRI), the Association for Cancer Immunotherapy (CIMT), the European Academy of Tumor Immunology (EATI), and the American Association for Cancer Research (AACR). The meeting is held every year and alternates between the United States and Europe. Through this collaboration, the organizations aim to more effectively and efficiently disseminate the latest cutting-edge information and research in cancer immunology and immunotherapy, and to provide an opportunity for teaching, learning, and networking among all stakeholders in the field.


Immuno-Oncology 360°

February 7-9, 2018
The Roosevelt Hotel, New York, New York

The 4th annual Immuno-Oncology 360° is a comprehensive program providing exposure to the entire spectrum of R&D, including the most up-to-date research, data and progress, to help foster collaboration across all IO stakeholders and transform the way cancer is treated.

With the support of educational partners The Association for Cancer Immunotherapy (CIMT), the Cancer Research Institute (CRI), The Society for Immunotherapy of Cancer (SITC) and the Patient Empowerment Network (PEN), IO360° attracts global experts and thought leaders from large pharma, biotech, investment community, academia and research organizations as part of the speaking faculty and attendees.

A 20% registration discount applies to CIMT members, using code CIMT.



CIMT Endeavour

Endeavour is a CIMT activity focusing on the translation and commercialization of cancer immunotherapies and diagnostics. Eandeavour workshops have allowed scientists from the cancer immunotherapy community to present their innovation to business experts and venture capital representatives with a focus on funding initiatives, viable business models and product development. Participants have shared and discussed the challenges that European and American biotech companies face in early, middle and late stage development.

CIMT Endeavour is supported by a grant of the Federal Ministry of Education and Research (BMBF).

To learn more, please go to